A Study on the Association of Serum 1,5-anhydroglucitol Levels and the Hyperglycaemic Excursions As Measured by Continuous Glucose Monitoring System Among People with Type 2 Diabetes in China

Overview

Journal Diabetes Metab Res Rev

Specialty Endocrinology

Date 2012 Jan 13

PMID 22238204

Citations 7

Authors

Y Wang

Y L Zhang

Y P Wang

C H Lei

Z L Sun

Affiliations

Soon will be listed here.

Abstract

Background: Blood glucose excursion is an important component of the glycaemic burden, but there are no indexes that can directly reflect them. The aim was to evaluate the values and significance of serum 1,5-anhydroglucitol (1,5-AG) in people with type 2 diabetes mellitus in China and to elucidate the relationship between 1,5-AG and traditional indexes of glycaemic excursions by continuous glucose monitoring.

Methods: A total of 576 healthy adults and 292 patients were included, and their 1,5-AG, fasting blood glucose and postprandial blood glucose and glycated haemoglobin were measured. For the 34 patients, their mean blood glucose, standard deviation of blood glucose, mean amplitude of glucose excursion, mean of daily differences, low blood glucose M-value index and the area under the curve for blood glucose above 180 mg/dL were calculated by use of a continuous glucose monitoring system.

Results: Serum levels of 1,5-AG among healthy adults were 28.44 ± 8.76 µg/mL with a significant gender bias rather than age bias. The 1,5-AG levels in people with type 2 diabetes mellitus were 4.57 ± 3.71 µg/mL, which were lower than those seen in the healthy adults. There was a correlation between 1,5-AG and glycated haemoglobin, fasting blood glucose, and postprandial blood glucose (r = -0.251, -0.195 and -0.349, respectively; all had p < 0.05). The continuous glucose monitoring system demonstrated that 1,5-AG presents a negative correlation with mean blood glucose, standard deviation of blood glucose, mean amplitude of glucose excursion and mean of daily differences for 7 days and with the area under the curve for blood glucose above 180 mg/dL on the third, fourth and seventh days.

Conclusions: 1,5-AG may serve as a marker of hyperglycaemia and 7-day hyperglycaemic excursions as well as being a useful adjunct to glycated haemoglobin for blood glucose monitoring in patients with diabetes.

Citing Articles

Plasma 1,5-anhydro-D-glucitol is associated with peripheral nerve function and diabetic peripheral neuropathy in patients with type 2 diabetes and mild-to-moderate hyperglycemia.

Xu F, Zhao L, Wang X, Wang C, Yu C, Zhang X Diabetol Metab Syndr. 2022; 14(1):24.

PMID: 35093139 PMC: 8800300. DOI: 10.1186/s13098-022-00795-z.

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome.

Su G, Gao M, Shi G, Dai X, Yao W, Zhang T Cardiovasc Diabetol. 2020; 19(1):71.

PMID: 32473648 PMC: 7261377. DOI: 10.1186/s12933-020-01045-0.

Data for serum 1,5 anhydroglucitol concentration in different populations.

Welter M, Boritza K, Anghebem-Oliveira M, Henneberg R, Hauser A, Rego F Data Brief. 2018; 20:753-760.

PMID: 30211270 PMC: 6129696. DOI: 10.1016/j.dib.2018.08.165.

Serum 1,5-anhydroglucitol when used with fasting plasma glucose improves the efficiency of diabetes screening in a Chinese population.

Ying L, He X, Ma X, Shen Y, Su H, Peng J Sci Rep. 2017; 7(1):11968.

PMID: 28931928 PMC: 5607288. DOI: 10.1038/s41598-017-12210-z.

Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance.

PramodKumar T, Jayashri R, Gokulakrishnan K, Velmurugan K, Pradeepa R, Anjana R Indian J Endocrinol Metab. 2016; 20(5):690-695.

PMID: 27730082 PMC: 5040052. DOI: 10.4103/2230-8210.190559.

References

Stenninger E, Lindqvist A, Aman J, Ostlund I, Schvarcz E . Continuous Subcutaneous Glucose Monitoring System in diabetic mothers during labour and postnatal glucose adaptation of their infants. Diabet Med. 2008; 25(4):450-4. DOI: 10.1111/j.1464-5491.2008.02416.x. View

Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna R, Moghetti P . Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000; 23(1):45-50. DOI: 10.2337/diacare.23.1.45. View

Robertson D, Alberti K, Dowse G, Zimmet P, Tuomilehto J, Gareeboo H . Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius Noncommunicable Diseases Study Group. Diabet Med. 1993; 10(1):56-60. DOI: 10.1111/j.1464-5491.1993.tb01997.x. View

Shi H, Fang J, Yang X, Shen Z, Zhu X . Serum 1,5-anhydro-D-glucitol as a new clinical marker for glucose metabolism in type 2 diabetics. Chin Med J (Engl). 2001; 112(6):571-3. View

Nguyen T, Rodriguez L, Mason K, Heptulla R . Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr Diabetes. 2007; 8(4):214-9. DOI: 10.1111/j.1399-5448.2007.00228.x. View

McDonnell C, Donath S, Vidmar S, Werther G, Cameron F . A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther. 2005; 7(2):253-63. DOI: 10.1089/dia.2005.7.253. View

Dworacka M, Winiarska H . The application of plasma 1,5-anhydro-D-glucitol for monitoring type 2 diabetic patients. Dis Markers. 2005; 21(3):127-32. PMC: 3850583. DOI: 10.1155/2005/251068. View

Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H . Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients. Diabetologia. 1988; 31(11):831-5. DOI: 10.1007/BF00277486. View

Schmitz O, Juhl C, Lund S, Djurhuus C, Nyholm B, Porksen N . HbA1c does not reflect prandial plasma glucose excursions in type 2 diabetes. Diabetes Care. 2000; 23(12):1859-60. DOI: 10.2337/diacare.23.12.1859. View

10.

Nowatzke W, Sarno M, Birch N, Stickle D, Eden T, Cole T . Evaluation of an assay for serum 1,5-anhydroglucitol (GlycoMark) and determination of reference intervals on the Hitachi 917 analyzer. Clin Chim Acta. 2004; 350(1-2):201-9. DOI: 10.1016/j.cccn.2004.08.013. View

11.

Jones S, Saunders H, Qi W, Pollock C . Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia. 1999; 42(9):1113-9. DOI: 10.1007/s001250051279. View

12.

Rodbard D . Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009; 11 Suppl 1:S55-67. DOI: 10.1089/dia.2008.0132. View

13.

Koehler C, Henkel E, LEONHARDT W, Fuecker K, Hanefeld M . Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000; 23(12):1830-4. DOI: 10.2337/diacare.23.12.1830. View

14.

Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J . Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362(12):1090-101. DOI: 10.1056/NEJMoa0908292. View

15.

Buse J, Freeman J, Edelman S, Jovanovic L, McGill J . Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol Ther. 2003; 5(3):355-63. DOI: 10.1089/152091503765691839. View

16.

Yamanouchi T, Akanuma H, Asano T, Konishi C, Akaoka I, Akanuma Y . Reduction and recovery of plasma 1,5-anhydro-D-glucitol level in diabetes mellitus. Diabetes. 1987; 36(6):709-15. DOI: 10.2337/diab.36.6.709. View

17.

MOLNAR G, Taylor W, Ho M . Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972; 8(5):342-8. DOI: 10.1007/BF01218495. View

18.

Dungan K, Buse J, Largay J, Kelly M, Button E, Kato S . 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care. 2006; 29(6):1214-9. DOI: 10.2337/dc06-1910. View

19.

Kovatchev B, Cox D, Kumar A, Gonder-Frederick L, Clarke W . Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther. 2003; 5(5):817-28. DOI: 10.1089/152091503322527021. View

20.

Kovatchev B, Cox D, Gonder-Frederick L, Young-Hyman D, Schlundt D, Clarke W . Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care. 1998; 21(11):1870-5. DOI: 10.2337/diacare.21.11.1870. View